Novel Drug Candidate Based on HSS Research Secures $70M Series A Financing and Will Begin Its First Clinical Trial in Europe
Hospital for Special SurgerySciRhom GmbH, a biotech startup co-founded by Hospital for Special Surgery (HSS), recently secured a 63 million euro (US$70 million) Series A financing round to support the clinical development of its novel drug candidate, SR-878. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors. This news follows the company’s recently received approval from Austrian regulatory authorities (BASG/AGES) required to commence its first-in-human Phase I clinical trial in Europe this fall.